Radiological assessment of immunotherapy effects and immune checkpoint‐related pneumonitis for lung cancer

Abstract

Immune checkpoint inhibitors (ICIs) therapy have revolutionized advanced lung cancer care. Interestingly, the host responses for patients received ICIs therapy are distinguishing from those with cytotoxic drugs, showing potential initial transient worsening of disease burden, pseudoprogression and delayed time to treatment response. Thus, a new imaging criterion to evaluate the response for immunotherapy should be developed. ICIs treatment is associated with unique adverse events, including potential life‐threatening immune checkpoint inhibitor‐related pneumonitis (ICI‐pneumonitis) if treated patients are not managed promptly. Currently, the diagnosis and clinical management of ICI‐pneumonitis remain challenging. As the clinical manifestation is often nonspecific, computed tomography (CT) scan and X‐ray films play important roles in diagnosis and triage. This article reviews the complications of immunotherapy in lung cancer and illustrates various radiologic patterns of ICI‐pneumonitis. Additionally, it is tried to differentiate ICI‐pneumonitis from other pulmonary pathologies common to lung cancer such as radiation pneumonitis, bacterial pneumonia and coronavirus disease of 2019 (COVID‐19) infection in recent months. Maybe it is challenging to distinguish radiologically but clinical presentation may help.

Therapeutic efficacy of rare earth carbonate with chemoradiotherapy in late-stage non-small cell lung cancer: a cohort prospective study

“…Meanwhile, REC inhibiting PD-1 and PD-L1 can exacerbate this response. In this study, the incidence of radiation pneumonitis in the experimental and control groups were 31.91% and 25.89%, respectively, with the experimental group showing a 23.25% increase compared to the control group (38,(56)(57)(58). A study by Tong etal (59) found that the combination of chemoradiotherapy and PD-1/PD-L1 inhibitors increased the i n c i d e n c e o f p n e u m o n i t i s b y 2 5 .…”